Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00528879 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 915
- Enrollment target
NCT00528879: Completed Phase 3 study, sponsored by AstraZeneca.
NCT00528879 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 915 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (19% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00528879, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 915 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn whether dapagliflozin can help reduce blood sugar levels in participants with Type 2 diabetes that is not well controlled on metformin alone. The safety of this treatment will also be studied.
Primary Outcome
HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtai
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 915 participants |
| Start Date | 2007-09 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
What the finished NCT00528879 record still lists
NCT00528879 is an interventional study that assigns participants to a tested intervention. The registered 915 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (19% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00528879 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00528879 about?
NCT00528879 is a clinical study titled "A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone". The purpose of this clinical research study is to learn whether dapagliflozin can help reduce blood sugar levels in participants with Type 2 diabetes that is not well controlled on metformin alone. The safety of this treatment will also be studied.
What is the current status of trial NCT00528879?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 915 participants. The study started on 2007-09. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00528879?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT00528879?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00528879's enrollment target sits among peer trials
915 347th of 2000 higher than 1,654 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06131840 · 914 participants · Phase 1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- NCT05739955 · 918 participants · NA
Impact of Enhanced Daily Disinfection on Environmental Contamination in Hospital Rooms
- NCT04589845 · 920 participants · Phase 2
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
- NCT06109870 · 920 participants · NA
Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia